Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tuesday, March 03, 2026

2 months
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (22) hot


In Detail Full day, Tuesday, March 03, 2026, Timezone: America/Chicago

Novo Nordisk inks $2.1B oral obesity drug deal

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Gubra plots Roivant-like model as partnered obesity drugs take flight

2 months / endpoints / Kyle LaHucik

Pfizer gets obesity drug approval in China shortly after buying local rights

2 months / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

2 months / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

2 months / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

2 months / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

2 months / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

2 months / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

2 months / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

2 months / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

2 months / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

2 months / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

2 months / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

2 months / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

2 months / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

2 months / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

2 months / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

2 months / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

2 months / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

2 months / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

2 months / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

3 months / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

3 months / endpoints / Kyle LaHucik

Back to Top / Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 22 stories in 2 months /



StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Development, Zoonotic Disease, Government Policy, Biotech and look for the RSS link.

More StackHealth



Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.